The landscape of cardiovascular aging research has shifted following a recent discovery regarding asprosin, a hormone produced by aging adipose (fat) tissue. A collaborative team of international researchers has linked the protein directly to mitochondrial dysfunction and cellular senescence

within endothelial cells, the delicate lining of blood vessels. This breakthrough sheds light on the complex biological mechanisms that degrade vascular health over time, offering a potential new target for therapeutic interventions aimed at mitigating age-related cardiovascular decline.

The study, published in the scientific journal Aging Cell, investigates how systemic signals originating in fat tissue communicate with and damage the cardiovascular system. As populations worldwide age, understanding the molecular crosstalk between metabolic organs like fat tissue and the circulatory system has become a primary objective for biogerontologists and cardiologists alike.

Vulnerable Vessels and the Mechanics of Cellular Senescence

Cellular senescence—a state in which cells permanently stop dividing yet remain metabolically active—is a hallmark of biological aging. Senescent cells do not quietly fade away; instead, they secrete a complex cocktail of inflammatory proteins, growth factors, and enzymes known as the senescence-associated secretory phenotype (SASP). Released directly into the bloodstream, SASP components act as biochemical messengers of decay, bathing neighboring and distant tissues in inflammatory signals.

Endothelial cells, which form the vital inner lining of blood vessels, are particularly vulnerable to this circulating toxic brew. These cells are responsible for regulating vascular tone, controlling blood pressure, and preventing clot formation. When damaged by SASP, endothelial function deteriorates, leading to arterial stiffness, hypertension, and an increased risk of cardiovascular events. Until now, medical science has lacked targeted interventions capable of directly shielding endothelial cells from the relentless onslaught of circulating senescence-associated factors.

Central to the new investigation is the cGAS-STING pathway, an innate immune signaling mechanism that has increasingly drawn the attention of researchers studying inflammatory and age-related pathologies. Under normal circumstances, the cGAS-STING pathway detects foreign microbial DNA in the cell’s cytoplasm. However, during aging, damaged cellular components—particularly mitochondrial DNA (mtDNA)—can leak into the cytosol. This mislocalized DNA erroneously triggers the STING receptor, setting off a cascade of chronic, sterile inflammation that accelerates tissue aging.

A Targeted Investigation into Asprosin

To untangle the complex web connecting metabolic dysfunction to vascular aging, the researchers turned their focus to asprosin. Discovered relatively recently, asprosin is a protein hormone encoded by the FBN1 gene and secreted primarily by white adipose tissue. It functions as a systemic metabolic regulator, influencing glucose homeostasis and appetite. Previous work by various scientific groups had already implicated asprosin in several pathological states, including diabetic nephropathy, where it damages renal tubular epithelial cells, as well as general vascular inflammation driven by hyperlipidemia.

Building upon this foundation, the researchers sought to determine whether asprosin plays a direct role in driving mitochondrial dysfunction and activating the cGAS-STING pathway in endothelial cells. The research team employed a multi-pronged methodological approach, combining in vitro cell cultures with sophisticated in vivo mouse models to trace the cascade of events from fat-derived protein to vascular structural decay.

Chronology and Experimental Findings

The investigation began by evaluating baseline asprosin levels across different age groups and experimental models. Unsurprisingly, the researchers observed that asprosin expression is significantly upregulated during cellular senescence in human endothelial cells and increases markedly with age in wild-type mice.

To observe the direct consequences of elevated asprosin and systemic senescence, the team established a accelerated aging mouse model using D-galactose, a reducing sugar frequently used to induce oxidative stress and cellular senescence in laboratory settings. A subset of these D-galactose-treated mice was subsequently administered an anti-asprosin antibody (AASP) to neutralize the circulating protein.

The therapeutic administration of AASP yielded promising results. As hypothesized, neutralizing asprosin ameliorated several negative physiological outcomes. Treated mice exhibited reduced systemic levels of various senescence biomarkers and circulating inflammatory cytokines. Furthermore, histological analysis revealed that vascular structural alterations typically induced by D-galactose—such as abnormal thickening of blood vessel walls and pathological collagen accumulation—were significantly mitigated in the AASP-treated cohort.

To confirm these findings through genetic ablation, the researchers also utilized a genetically engineered mouse model incapable of natively producing asprosin. When subjected to the same D-galactose aging protocol, these asprosin-deficient mice displayed a similar resistance to accelerated vascular aging, featuring attenuated inflammatory markers and preserved vascular architecture compared to control mice that retained the ability to produce the protein.

Complementary in vitro experiments using conditioned media harvested from cultured adipocytes reinforced these conclusions. Adipocytes incapable of producing asprosin secreted factors that proved markedly protective for human endothelial cells. When exposed to this healthy conditioned media, endothelial cells exhibited greater resilience against hydrogen peroxide-induced oxidative stress, alongside enhanced cellular proliferation and migration capabilities.

Mitochondrial Collapse and the STING Connection

At the subcellular level, the researchers unmasked the precise mechanism by which asprosin inflicts damage. Treating endothelial cells with asprosin produced cellular disruptions remarkably similar to those caused by hydrogen peroxide, leading directly to the degradation of mitochondrial membranes and extensive mitochondrial fragmentation. When hydrogen peroxide and asprosin were administered in tandem, the destructive synergistic effect intensified.

Crucially, the study revealed that asprosin exposure forces mitochondrial DNA to leak out of the organelles and into the cell’s cytosol. As anticipated, this cytosolic mtDNA accumulation acted as a direct trigger for the cGAS-STING pathway. When the researchers genetically knocked down STING expression in these cells, the downstream signaling cascade was interrupted, successfully preventing the induction of cellular senescence.

Further analysis connected this mtDNA leakage to an overproduction of mitochondrial reactive oxygen species (mtROS). By treating the cells with mitoTEMPO—a targeted antioxidant that specifically scavenges mtROS—the scientists were able to block much of the asprosin-induced damage, effectively halting mtDNA leakage, suppressing senescence biomarkers, and restoring healthy cellular proliferation rates.

Broader Implications and Future Therapeutic Horizons

While asprosin represents a compelling and viable link between fat tissue dysfunction and vascular aging, the researchers remain measured in their assessment of its clinical translation. Asprosin is cleaved from profibrillin-1, a product of the FBN1 gene, the expression of which naturally rises during the senescence process. However, the study’s authors emphasize that while a clear pathophysiological axis connecting asprosin, mitochondrial decay, and endothelial senescence has been established, the complete upstream regulatory network driving asprosin upregulation during natural aging requires further elucidation.

Furthermore, translational researchers point out crucial questions regarding clinical utility. It remains undetermined whether targeted anti-asprosin therapies would offer incremental clinical benefits over existing standard-of-care treatments for hypertension, atherosclerosis, and age-related cardiovascular diseases. Consequently, the research team advises that any future pharmacological agents designed to inhibit asprosin or its downstream signaling partners should be rigorously evaluated in combination with current cardiovascular therapeutics rather than as isolated standalone treatments.

As the scientific community continues to map the intricate molecular pathways of biological aging, studies of this nature underscore the profound communication network existing between metabolic tissues and the cardiovascular system. By identifying specific circulating proteins like asprosin that translate fat tissue pathology into vascular decay, researchers are steadily drawing closer to precision therapies capable of preserving cardiovascular resilience well into advanced age.

By Basiran